On February 6, 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, reported that the Company presented a talk during the plenary session of the joint AACR (Free AACR Whitepaper)-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) agonist, KROS101 (Press release, Kairos Pharma, FEB 6, 2025, View Source [SID1234650094]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the talk, titled, "KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment," recent findings from the Company’s in vivo work on the compound was presented. The results, which can be found here, demonstrated that KROS 101 is a potent GITR ligand agonist that enhances T cell infiltration, proliferation, and ability to kill cancer cells in mouse models of melanoma and in human glioblastoma in vitro, while effectively reducing T reg-mediated suppression. KROS 101 showed significant activity in enabling T cell proliferation and killing of melanoma tumors in vivo as well as glioblastoma tumor in vitro.
GITRL, one of the checkpoint cytokines in the family of tumor necrosis factor ligand family, regulates T cell function in autoimmunity and cancer. KROS 101 stabilizes the active form of GITRL and thereby reduces suppressive T-cells and enhances cytotoxic T cells. In a preclinical study, KROS 101 reduced melanoma tumor in a human GITR knock-in mouse model compared to those in mice treated with the GITR antibody TRX518, which was recently in clinical trials for solid cancers.
Dr. Ramachandran Murali, VP of Research and Development at Kairos Pharma and co-inventor of KROS 101, stated, "The performance of KROS 101 as a central mediator of T cell expansion in cancer has been supported by these studies."
Dr. John Yu, CEO of Kairos Pharma and co-inventor, added that "the preclinical data support the potential to exploit GITR as a lever for T cell expansion and novel therapy for cancer."
The American Association for Cancer Research (AACR) (Free AACR Whitepaper) and Japanese Cancer Association (JCA) hosted the 13th AACR (Free AACR Whitepaper)-JCA Joint Conference from February 1-5, 2025 at the Hyatt Regency Maui, in Maui, Hawaii. The meeting series has a long tradition of bringing together outstanding researchers from the United States, Japan, and around the world to share their findings and present the latest advances in basic, translational, and clinical cancer research.